Realm Therapeutics plc (RLM), a clinical stage bio-pharmaceutical company focused on developing novel therapeutics in immune-related diseases based on its proprietary hypochlorous acid (HOCl) technology, has reported preliminary top-line data from its Phase II trial of PR022 in Atopic Dermatitis, in tandem with H1’18 financial results.
